Depletion of the gut microbiota enhances the blood pressure-lowering effect of captopril: implication of the gut microbiota in resistant hypertension.
Blood pressure
Captopril efficacy
Gut microbiota
Resistant hypertension
Journal
Hypertension research : official journal of the Japanese Society of Hypertension
ISSN: 1348-4214
Titre abrégé: Hypertens Res
Pays: England
ID NLM: 9307690
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
13
12
2021
accepted:
22
03
2022
revised:
08
03
2022
pubmed:
6
5
2022
medline:
19
8
2022
entrez:
5
5
2022
Statut:
ppublish
Résumé
The role of the gut microbiota in the initiation and progression of hypertension has been newly identified, suggesting that targeting the gut microbiota may provide a new treatment strategy. This entails a complicated interaction between the gut microbiota and different host systems (e.g., immune system) or organs (e.g., gut, spleen) that contribute to blood pressure control. The significance of the gut microbiota in treatment-resistant hypertension is still unknown, owing to a lack of appropriate animal models. Given that the gut microbiota has a variety of enzymatic activities, we hypothesized that the gut microbiota may be involved in the metabolism of antihypertensive medications, causing treatment-resistant hypertension. We investigated this hypothesis in a simple, new hypertension paradigm and found that hypertensive rats pretreated with antibiotics to reduce the gut microbiota had a better response to the angiotensin-converting enzyme inhibitor captopril. This is a simple rodent model for testing the effectiveness of antihypertensive medications. Further mechanistic research may shed light on the pathogenic function of the gut microbiota in resistant hypertension. Our method presents a novel model that has the potential to be employed in the research of resistant hypertension.
Identifiants
pubmed: 35513487
doi: 10.1038/s41440-022-00921-4
pii: 10.1038/s41440-022-00921-4
doi:
Substances chimiques
Antihypertensive Agents
0
Captopril
9G64RSX1XD
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1505-1510Informations de copyright
© 2022. The Author(s), under exclusive licence to The Japanese Society of Hypertension.
Références
Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16:223–37.
doi: 10.1038/s41581-019-0244-2
Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of apparent treatment-resistant hypertension in the United States. Hypertension. 2019;73:424–31.
doi: 10.1161/HYPERTENSIONAHA.118.12191
Siddiqui M, Dudenbostel T, Calhoun DA. Resistant and refractory hypertension: antihypertensive treatment resistance vs treatment failure. Can. J. Cardiol. 2016;32:603–6.
Lohmeier TE, Hall JE. Device-based neuromodulation for resistant hypertension therapy. Circ Res. 2019;124:1071–93.
doi: 10.1161/CIRCRESAHA.118.313221
Raizada MK, Joe B, Bryan NS, Chang EB, Dewhirst FE, Borisy GG, et al. Report of the national heart, lung, and blood institute working group on the role of microbiota in blood pressure regulation: current status and future directions. Hypertension. 2017;70:479–85.
Yang T, Aquino V, Lobaton GO, Li H, Colon-Perez L, Goel R, et al. Sustained captopril-induced reduction in blood pressure is associated with alterations in gut-brain axis in the spontaneously hypertensive rat. J Am Heart Assoc. 2019;8:e010721.
doi: 10.1161/JAHA.118.010721
Li HB, Yang T, Richards EM, Pepine CJ, Raizada MK. Maternal treatment with captopril persistently alters gut-brain communication and attenuates hypertension of male offspring. Hypertension. 2020;75:1315–24.
doi: 10.1161/HYPERTENSIONAHA.120.14736
Kripalani KJ, McKinstry DN, Singhvi SM, Willard DA, Vukovich RA, Migdalof BH. Disposition of captopril in normal subjects. Clin Pharm Ther. 1980;27:636–41.
doi: 10.1038/clpt.1980.90
Qi Y, Aranda JM, Rodriguez V, Raizada MK, Pepine CJ. Impact of antibiotics on arterial blood pressure in a patient with resistant hypertension - a case report. Int J Cardiol. 2015;201:157–8.
doi: 10.1016/j.ijcard.2015.07.078
Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature 2019;570:462–7.
doi: 10.1038/s41586-019-1291-3
Yang T, Mei X, Tackie-Yarboi E, Kyoung J, Mell B, Yeo JY, et al. Identification of a gut microbe that attenuates the blood pressure lowering effect of ACEi Quinapril. Hypertension. 2021;78:AMP38. https://doi.org/10.1161/hyp.78.suppl_1.MP38
doi: 10.1161/hyp.78.suppl_1.MP38
Santisteban MM, Ahmari N, Carvajal JM, Zingler MB, Qi Y, Kim S, et al. Involvement of bone marrow cells and neuroinflammation in hypertension. Circ Res. 2015;117:178–91.
doi: 10.1161/CIRCRESAHA.117.305853
Mell B, Jala VR, Mathew AV, Byun J, Waghulde H, Zhang Y, et al. Evidence for a link between gut microbiota and hypertension in the Dahl rat. Physiol Genom. 2015;47:187–97.
doi: 10.1152/physiolgenomics.00136.2014
Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, et al. Gut dysbiosis is linked to hypertension. Hypertension. 2015;65:1331–40.
doi: 10.1161/HYPERTENSIONAHA.115.05315
Joe B, McCarthy CG, Edwards JM, Cheng X, Chakraborty S, Yang T, et al. Microbiota introduced to germ-free rats restores vascular contractility and blood pressure. Hypertension. 2020;76:1847–55.
doi: 10.1161/HYPERTENSIONAHA.120.15939
Karbach SH, Schönfelder T, Brandão I, Wilms E, Hörmann N, Jäckel S, et al. Gut microbiota promote angiotensin ii-induced arterial hypertension and vascular dysfunction. J. Am. Heart Assoc. 2016;5:e003698.
Cheema MU, Pluznick JL. Gut microbiota plays a central role to modulate the plasma and fecal metabolomes in response to angiotensin II. Hypertension. 2019;74:184–93.
doi: 10.1161/HYPERTENSIONAHA.119.13155